0001213900-26-055823
SEC filingMDxHealth announced Q1-2026 results and a strategic decision to discontinue its Resolve UTI business and Plano lab operations due to unsustainable reimbursement uncertainty, while reaffirming a revised 2026 core cancer revenue guidance of $110–115 million.
MDxHealth’s Q1-2026 results reflect a pivotal strategic inflection point: the company reported $27.4 million in revenue (+13% YoY), yet simultaneously exited its Resolve UTI business — a decision driven not by clinical or commercial failure, but by an abrupt, unexplained reversal in Medicare reimbursement policy by Novitas Solutions for its Texas lab. Management explicitly tied the discontinuation to reimbursement volatility, calling it 'unsustainable' despite 'urgent clinical need.' This exit reshapes the financial profile: pro-forma adjusted core revenue (excluding Resolve) was $23.9 million (+11% YoY), and the company issued revised full-year 2026 guidance of $110–115 million for its prostate cancer diagnostics alone — implying deliberate de-emphasis of non-core assets. Margin pressure emerged as gross margin contracted 310 bps to 60.7%, attributed directly to test mix — with tissue-based tests falling to 66% of Q1-2026 revenue (down from 85% in Q1-2025), while liquid-based volume more than doubled (+128% YoY), reflecting ExoDx integration. Operating expenses rose 19% YoY, primarily due to ExoDx-related headcount and costs. Critically, the $10.4 million Novitas recoupment demand is treated as a contingent liability with no accrual — underscoring material uncertainty in near-term cash flow and regulatory risk exposure. The forward-looking AI initiative and PROTECT trial enhancements signal long-term repositioning toward scalable, data-driven urologic oncology diagnostics, but near-term execution hinges on stabilizing reimbursement for its GPS and Confirm platforms amid ongoing payer scrutiny.